论文部分内容阅读
目的探讨拉米夫定联合阿德福韦酯治疗活动性乙型肝炎肝硬化的临床效果。方法活动性乙型肝炎肝硬化患者56例,采用抽签方法将其随机分为观察组(26例)和对照组(30例),分析比较两组患者在术后的康复状况。结果总结资料及统计学分析表明,观察组患者治疗总有效率为96.2%,对照组患者治疗总有效率为76.7%,观察组患者治疗总有效率显著优于对照组,差异有统计学意义(P<0.05)。结论使用拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化患者,可取得较好的临床疗效,效益风险比较高,值得推广。
Objective To investigate the clinical effect of lamivudine combined with adefovir dipivoxil on active hepatitis B cirrhosis. Methods Fifty-six patients with active hepatitis B cirrhosis were randomly divided into observation group (n = 26) and control group (n = 30) by random sampling. The rehabilitation status of the two groups was analyzed. Results of the summary data and statistical analysis showed that the total effective rate of treatment group was 96.2% in observation group and 76.7% in control group, and the total effective rate of observation group was significantly better than that of control group (the difference was statistically significant ( P <0.05). Conclusions The use of lamivudine combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis patients can achieve better clinical efficacy, the risk of benefit is relatively high, it is worth to promote.